Group One Trading
BTAI icon

Group One Trading’s BioXcel Therapeutics BTAI Stock Holding History

Group One Trading’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Sell
1
-3,184
-100% -$5.24K ﹤0.01% 7488
2025
Q4 		$5.1K Buy
3,185
+936
+42% +$1.93K ﹤0.01% 7177
2025
Q3 		$5.76K Buy
2,249
+976
+77% +$3.08K ﹤0.01% 7468
2025
Q2 		$2.3K Hold
1,273
– – ﹤0.01% 7377
2025
Q1 		$2.58K Buy
1,273
+141
+12% +$526 ﹤0.01% 6917
2024
Q4 		$6.77K Sell
1,132
-753
-40% -$6.29K ﹤0.01% 6291
2024
Q3 		$18.4K Buy
+1,885
New +$25.3K ﹤0.01% 5277
2023
Q4 		– Sell
-2,409
Closed -$134K – 7420
2023
Q3 		$97.5K Buy
+2,409
New +$244K ﹤0.01% 4480
2023
Q2 		– Sell
-24
Closed -$7.99K – 7671
2023
Q1 		$7.28K Sell
24
-1,864
-99% -$796K ﹤0.01% 6120
2022
Q4 		$649K Buy
+1,888
New +$456K ﹤0.01% 2800
2022
Q3 		– Sell
-303
Closed -$70.3K – 7567
2022
Q2 		$64K Sell
303
-309
-50% -$65K ﹤0.01% 5352
2022
Q1 		$205K Buy
612
+352
+135% +$102K ﹤0.01% 4771
2021
Q4 		$85K Sell
260
-486
-65% -$209K ﹤0.01% 5869
2021
Q3 		$362K Sell
746
-103
-12% -$45.3K ﹤0.01% 4546
2021
Q2 		$395K Sell
849
-268
-24% -$146K ﹤0.01% 4485
2021
Q1 		$772K Sell
1,117
-82
-7% -$66K ﹤0.01% 3531
2020
Q4 		$886K Sell
1,199
-629
-34% -$490K ﹤0.01% 2755
2020
Q3 		$1.27M Buy
1,828
+293
+19% +$220K ﹤0.01% 1982
2020
Q2 		$1.3M Sell
1,535
-714
-32% -$466K 0.01% 1799
2020
Q1 		$804K Buy
+2,249
New +$808K 0.01% 1696

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Group One Trading's BTAI Position: Q1 2026 in Review

Group One Trading reduced its BioXcel Therapeutics (BTAI) stake by 100% in Q1 2026, selling an estimated $5.24K and leaving 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #7488.

Group One Trading first reported a position in BTAI in Q1 2020 and has held it in 20 quarters since. The position peaked at $1.3M in Q2 2020. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • Group One Trading held 1 share of BioXcel Therapeutics worth $1 as of Q1 2026.
  • Group One Trading sold 3,184 BioXcel Therapeutics shares in Q1 2026, an estimated $5.24K.
  • BioXcel Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #7488 holding.
  • Group One Trading first reported a position in BioXcel Therapeutics in Q1 2020 and has held it in 20 quarters since.
  • Group One Trading's BioXcel Therapeutics position peaked at $1.3M in Q2 2020.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.